Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Corporate Update (July 2017)
10 slides from Genocea Biosciences's corporate update, Jul 24, 2017
Slide 1: GEN-003 Positive Phase 2b Clinical Efficacy Results: 12-Month Top-line Results
GEN-003 Positive Phase 2b Clinical Efficacy Results Immunotherapy Candidate for Genital Herpes 12-Month Top-line Results Exhibit 99.2
Slide 2: Disclaimer
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: 12-Month Top-Line Clinical Data Highlights
• Statistically significant 49% reduction versus placebo in median genital lesion rate over 12 months for selected Phase 3 dose – Expected Phase 3 primary endpoint – Commercial-ready formulation • Positive results from other secondary clinical endpoints • No changes observed to the previously establ
Slide 4: Trial Design Recap
• Randomized, double-blind, placebo-controlled trial • 131 subjects with a history of recurrent genital herpes • 3 dose groups – Placebo (n=44) – 60 µg per antigen / 50 µg of Matrix-M adjuvant (n=43) – 60 µg per antigen / 75 µg of Matrix-M adjuvant (n=44) • Key elements consistent with prior GEN-003
Slide 5: Phase 3 Dose Significantly Reduces Genital Lesion Rate vs. Placebo over 12 Months
Wilcoxon Rank Sum test vs. placebo -49% p=0.01 -37%% reduction vs. placebo Notes: (1) Days with visible lesions divided by total days • 60/50 dose significant impact on genital lesion rate: – Reduction vs. placebo consistent with 52% reduction 6 months post dosing – Reductions vs. baseline consisten
Slide 6: Consistent, Positive Data From Secondary Clinical Endpoints at 60/50 Dose
6 Consistent, Positive Data From Secondary Clinical Endpoints at 60/50 Dose NS = p>0,05; (1) Wilcoxon Rank Sum test vs. placebo; (2) Log Rank Test; (3) Poisson mixed effect model with empirical variance
Slide 7: GEN-003 Phase 3 on Track to Start by End of 2017
Phase 2 extension 24 month • Demonstrated 2-year durability of effect 7 GEN-003 Phase 3 on Track to Start by End of 2017* 2017 12 month Phase 2b Phase 3 Program FDA EoP2 Regulatory Phase 2b maintenance dosing Antiviral combination • Demonstrated clinical, virologic efficacy • Confirmed dose & commer
Slide 8: GEN-003 Strongly Positioned Ahead of Phase 3
• Significant efficacy at expected Phase 3 primary endpoint at Phase 3 dose, using Phase 3 formulation – ~50% fewer days with genital lesions; fewer and shorter genital lesion outbreaks; • GEN-003 Phase 3 program on track to commence in 2017* • Potential new cornerstone treatment for patients with g
Slide 9: Q&A
Q&A 9
Slide 10: Investor and Media Contacts
Jonathan Poole Chief Financial Officer Phone: +1 617-876-8191 jonathan.poole@genocea.com Jennifer LaVin Media Relations/Corporate Communications Phone: +1 207-360-0473 jennifer.lavin@genocea.com Investor inquiries: Media inquiries: